Trinity Biotech (TRIB) shares jumped 50% in recent Tuesday trading after the company said the latest pre-pivotal clinical trial for its continuous glucose monitoring technology yielded "breakthrough" results.
The modular device, described as "disruptively affordable and user-friendly," offers better signal quality and sensor performance, and a 25% to 30% enhancement in the key accuracy indicator compared with other previously released Waveform CGM sensors, the company said Tuesday in a statement.
The trial, which involved 30 diabetic participants, also showed that the patented device's low blood sugar reading accuracy achieved parity with industry benchmarks, the company said.
The company expects to complete further clinical trials for device enhancements and is scheduled to file for regulatory approval in the EU this year and in the US in 2026.
Price: 1.14, Change: +0.38, Percent Change: +50.13
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.